Search

Your search keyword '"Tawatchai Suwanban"' showing total 2 results
Start Over Author "Tawatchai Suwanban" Publisher springer science and business media llc
2 results on '"Tawatchai Suwanban"'

1. Outcomes of polatuzumab vedotin-containing regimens in real-world setting of relapsed and or refractory diffuse large B-cell lymphoma patients: a matched-control analysis from the Thai Lymphoma Study Group (TLSG)

Author

Thanawat Rattanathammethee, Lalita Norasetthada, Udomsak Bunworasate, Kitsada Wudhikarn, Jakrawadee Julamanee, Panarat Noiperm, Theerin Lanamtieng, Pisa Phiphitaporn, Manassamon Navinpipat, Piyapong Kanya, Dusit Jit-ueakul, Somchai Wongkhantee, Thanongsak Suwannathen, Juthatip Chaloemwong, Peerapon Wong, Nisa Makruasi, Archrob Khuhapinant, Kannadit Prayongratana, Pimjai Niparuck, Nonglak Kanitsap, Tawatchai Suwanban, and Tanin Intragumtornchai

Subjects
Hematology, General Medicine
Published
2023

2. Secondary central nervous system relapse in diffuse large B cell lymphoma in a resource limited country: result from the Thailand nationwide multi-institutional registry

Author

Jakrawadee Julamanee, Pimjai Niparuck, Archrob Khuhapinant, Tanin Intragumtornchai, Nisa Makruasi, Arnuparp Lekhakula, Kanchana Chansung, Kannadit Prayongratana, Somchai Wongkhantee, Tontanai Numbenjapon, Lalita Norasetthada, Weerasak Nawarawong, Tawatchai Suwanban, Kitsada Wudhikarn, Nonglak Kanitsap, Udomsak Bunworasate, Supachai Ekwattanakit, Peerapon Wong, Pannee Praditsuktavorn, Suporn Chuncharunee, and Chittima Sirijerachai

Subjects
Adult, Male, medicine.medical_specialty, Adolescent, Central Nervous System Neoplasms, Young Adult, 03 medical and health sciences, 0302 clinical medicine, International Prognostic Index, Internal medicine, medicine, Humans, Cumulative incidence, Prospective Studies, Registries, Prospective cohort study, Aged, Aged, 80 and over, Univariate analysis, business.industry, Hematology, General Medicine, Middle Aged, Thailand, medicine.disease, Surgery, B symptoms, 030220 oncology & carcinogenesis, Health Resources, Female, Rituximab, Lymphoma, Large B-Cell, Diffuse, Neoplasm Recurrence, Local, medicine.symptom, business, Diffuse large B-cell lymphoma, Progressive disease, Follow-Up Studies, 030215 immunology, medicine.drug
Abstract

Secondary central nervous system (CNS) relapse is a serious and fatal complication of diffuse large B cell lymphoma (DLBCL). Data on secondary CNS (SCNS) relapse were mostly obtained from western countries with limited data from developing countries. We analyzed the data of 2034 newly diagnosed DLBCL patients enrolled into the multi-center registry under Thai Lymphoma Study Group from setting. The incidence, September 2006 to December 2013 to represent outcome from a resource limited pattern, management, and outcome of SCNS relapse were described. The 2-year cumulative incidence (CI) of SCNS relapse was 2.7 %. A total of 729, 1024, and 281 patients were classified as low-, intermediate-, and high-risk CNS international prognostic index (CNS-IPI) with corresponding 2-year CI of SCNS relapse of 1.5, 3.1, and 4.6 %, respectively (p

Published
2016

Catalog

Books, media, physical & digital resources
See catalog results